{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:52:57Z","timestamp":1791604377693,"version":"4.3.4"},"reference-count":54,"publisher":"Tohoku University Medical Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.1620\/tjem.2026.j037","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:09:40Z","timestamp":1778710180000},"page":"561-574","source":"Crossref","is-referenced-by-count":0,"title":["Dapagliflozin Alleviates Non-Alcoholic Fatty Liver Disease in Mice by Inhibiting Ferroptosis through Activating the SIRT1\/Nrf2 Pathway"],"prefix":"10.1620","volume":"269","author":[{"given":"Min","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, General Hospital of the Central Theater Command"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BiYing","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, General Hospital of the Central Theater Command"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, General Hospital of the Central Theater Command"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, General Hospital of the Central Theater Command"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"Androutsakos, T., Nasiri-Ansari, N., Bakasis, A.D., Kyrou, I., Efstathopoulos, E., Randeva, H.S. &amp; Kassi, E. (2022)  SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.  <i>Int. J. Mol. Sci.<\/i>, 23, 3107. https:\/\/doi.org\/10.3390\/ijms23063107","DOI":"10.3390\/ijms23063107"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Chambel, S.S., Santos-Goncalves, A. &amp; Duarte, T.L. (2015)  The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism.  <i>Biomed. Res. Int.<\/i>, 2015, 597134. https:\/\/doi.org\/10.1155\/2015\/597134","DOI":"10.1155\/2015\/597134"},{"key":"3","doi-asserted-by":"publisher","unstructured":"Chen, D., Shi, J., Wu, Y., Miao, L., Wang, Z., Wang, Y., Xu, S. &amp; Lou, Y. (2025)  Dapagliflozin alleviates high-fat-induced obesity cardiomyopathy by inhibiting ferroptosis.  <i>ESC Heart Fail.<\/i>, 12, 1358-1373. https:\/\/doi.org\/10.1002\/ehf2.15150","DOI":"10.1002\/ehf2.15150"},{"key":"4","doi-asserted-by":"publisher","unstructured":"Chen, J., Li, X., Ge, C., Min, J. &amp; Wang, F. (2022)  The multifaceted role of ferroptosis in liver disease.  <i>Cell Death Differ.<\/i>, 29, 467-480. https:\/\/doi.org\/10.1038\/s41418-022-00941-0","DOI":"10.1038\/s41418-022-00941-0"},{"key":"5","doi-asserted-by":"publisher","unstructured":"Chen, W., Zhang, Y., Wang, Z., Tan, M., Lin, J., Qian, X., Li, H. &amp; Jiang, T. (2023)  Dapagliflozin alleviates myocardial ischemia\/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition.  <i>Front. Pharmacol.<\/i>, 14, 1078205. https:\/\/doi.org\/10.3389\/fphar.2023.1078205","DOI":"10.3389\/fphar.2023.1078205"},{"key":"6","doi-asserted-by":"publisher","unstructured":"Chen, Z., Tian, R., She, Z., Cai, J. &amp; Li, H. (2020)  Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease.  <i>Free Radic. Biol. Med.<\/i>, 152, 116-141. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.02.025","DOI":"10.1016\/j.freeradbiomed.2020.02.025"},{"key":"7","doi-asserted-by":"publisher","unstructured":"Cobbina, E. &amp; Akhlaghi, F. (2017)  Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.  <i>Drug Metab. Rev.<\/i>, 49, 197-211. https:\/\/doi.org\/10.1080\/03602532.2017.1293683","DOI":"10.1080\/03602532.2017.1293683"},{"key":"8","doi-asserted-by":"publisher","unstructured":"Colak, Y., Ozturk, O., Senates, E., Tuncer, I., Yorulmaz, E., Adali, G., Doganay, L. &amp; Enc, F.Y. (2011)  SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease.  <i>Med. Sci. Monit.<\/i>, 17, HY5-9. https:\/\/doi.org\/10.12659\/MSM.881749","DOI":"10.12659\/MSM.881749"},{"key":"9","doi-asserted-by":"publisher","unstructured":"Della Torre, S., Dell\u2019Omo, G., Dellavedova, J., Palazzolo, L., Scanziani, E., Eberini, I., Pinto, A., Mitro, N., Conti, P., Villa, A. &amp; Ciana, P. (2024)  Discovery and characterization of a new class of NAD(+)-independent SIRT1 activators.  <i>Pharmacol.<\/i><i> Res.<\/i>, 206, 107296. https:\/\/doi.org\/10.1016\/j.phrs.2024.107296","DOI":"10.1016\/j.phrs.2024.107296"},{"key":"10","doi-asserted-by":"publisher","unstructured":"Dhillon, S. (2019)  Dapagliflozin: A Review in Type 2 Diabetes.  <i>Drugs<\/i>, 79, 1135-1146. https:\/\/doi.org\/10.1007\/s40265-019-01148-3","DOI":"10.1007\/s40265-019-01148-3"},{"key":"11","doi-asserted-by":"publisher","unstructured":"Dodson, M., Castro-Portuguez, R. &amp; Zhang, D.D. (2019)  NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis.  <i>Redox Biol.<\/i>, 23, 101107. https:\/\/doi.org\/10.1016\/j.redox.2019.101107","DOI":"10.1016\/j.redox.2019.101107"},{"key":"12","doi-asserted-by":"publisher","unstructured":"Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M. &amp; Sanyal, A.J. (2018)  Mechanisms of NAFLD development and therapeutic strategies.  <i>Nat. Med.<\/i>, 24, 908-922. https:\/\/doi.org\/10.1038\/s41591-018-0104-9","DOI":"10.1038\/s41591-018-0104-9"},{"key":"13","doi-asserted-by":"publisher","unstructured":"Han, J., Li, S., Wang, W., Jiang, X., Liu, C., Lei, L., Li, Y., Sheng, R., Zhang, Y., Wu, Y., Zhang, J., Zhang, Y., Xu, Y. &amp; Si, S. (2023a)  SIRT1 Activator E1231 Alleviates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism.  <i>Curr. Issues Mol. Biol.<\/i>, 45, 5052-5070. https:\/\/doi.org\/10.3390\/cimb45060321","DOI":"10.3390\/cimb45060321"},{"key":"14","doi-asserted-by":"publisher","unstructured":"Han, S.K., Baik, S.K. &amp; Kim, M.Y. (2023b)  Non-alcoholic fatty liver disease: Definition and subtypes.  <i>Clin. Mol. Hepatol.<\/i>, 29, S5-S16. https:\/\/doi.org\/10.3350\/cmh.2022.0424","DOI":"10.3350\/cmh.2022.0424"},{"key":"15","doi-asserted-by":"publisher","unstructured":"Han, T., Fan, Y., Gao, J., Fatima, M., Zhang, Y., Ding, Y., Bai, L. &amp; Wang, C. (2021)  Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice.  <i>Adipocyte<\/i>, 10, 446-455. https:\/\/doi.org\/10.1080\/21623945.2021.1979277","DOI":"10.1080\/21623945.2021.1979277"},{"key":"16","doi-asserted-by":"publisher","unstructured":"Kerins, M.J. &amp; Ooi, A. (2018)  The Roles of NRF2 in Modulating Cellular Iron Homeostasis.  <i>Antioxid. Redox Signal.<\/i>, 29, 1756-1773. https:\/\/doi.org\/10.1089\/ars.2017.7176","DOI":"10.1089\/ars.2017.7176"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., Ferrell, L.D., Liu, Y.C., Torbenson, M.S., Unalp-Arida, A., Yeh, M., McCullough, A.J., Sanyal, A.J. &amp; Nonalcoholic Steatohepatitis Clinical Research Network (2005)  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.  <i>Hepatology<\/i>, 41, 1313-1321. https:\/\/doi.org\/10.1002\/hep.20701","DOI":"10.1002\/hep.20701"},{"key":"18","doi-asserted-by":"publisher","unstructured":"Latva-Rasku, A., Honka, M.J., Kullberg, J., Mononen, N., Lehtimaki, T., Saltevo, J., Kirjavainen, A.K., Saunavaara, V., Iozzo, P., Johansson, L., Oscarsson, J., Hannukainen, J.C. &amp; Nuutila, P. (2019)  The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.  <i>Diabetes Care<\/i>, 42, 931-937. https:\/\/doi.org\/10.2337\/dc18-1569","DOI":"10.2337\/dc18-1569"},{"key":"19","doi-asserted-by":"publisher","unstructured":"Li, B., Xiao, Q., Zhao, H., Zhang, J., Yang, C., Zou, Y., Zhang, B., Liu, J., Sun, H. &amp; Liu, H. (2024)  Schisanhenol ameliorates non-alcoholic fatty liver disease via inhibiting miR-802 activation of AMPK-mediated modulation of hepatic lipid metabolism.  <i>Acta Pharm. Sin. B<\/i>, 14, 3949-3963. https:\/\/doi.org\/10.1016\/j.apsb.2024.05.014","DOI":"10.1016\/j.apsb.2024.05.014"},{"key":"20","doi-asserted-by":"publisher","unstructured":"Li, C., Deng, D., Jiang, Q., Shi, J., Xu, L. &amp; Liu, Y. (2025)  Ferroptosis in NAFLD: insights and the therapeutic potential of exercise.  <i>Front. Med. <\/i>(<i>Lausanne<\/i>), 12, 1462145. https:\/\/doi.org\/10.3389\/fmed.2025.1462145","DOI":"10.3389\/fmed.2025.1462145"},{"key":"21","doi-asserted-by":"publisher","unstructured":"Li, X., Wang, T.X., Huang, X., Li, Y., Sun, T., Zang, S., Guan, K.L., Xiong, Y., Liu, J. &amp; Yuan, H.X. (2020)  Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity.  <i>Liver Int.<\/i>, 40, 1378-1394. https:\/\/doi.org\/10.1111\/liv.14428","DOI":"10.1111\/liv.14428"},{"key":"22","doi-asserted-by":"publisher","unstructured":"Lin, X.F., Cui, X.N., Yang, J., Jiang, Y.F., Wei, T.J., Xia, L., Liao, X.Y., Li, F., Wang, D.D., Li, J., Wu, Q., Yin, D.S., Le, Y.Y., Yang, K., Wei, R., et al. (2024)  SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization.  <i>Acta <\/i><i>Pharmacol. Sin.<\/i>, 45, 2579-2597. https:\/\/doi.org\/10.1038\/s41401-024-01389-3","DOI":"10.1038\/s41401-024-01389-3"},{"key":"23","doi-asserted-by":"publisher","unstructured":"Mun, J., Kim, S., Yoon, H.G., You, Y., Kim, O.K., Choi, K.C., Lee, Y.H., Lee, J., Park, J. &amp; Jun, W. (2019)  Water Extract of Curcuma longa L. Ameliorates Non-Alcoholic Fatty Liver Disease.  <i>Nutrients<\/i>, 11, 2536. https:\/\/doi.org\/10.3390\/nu11102536","DOI":"10.3390\/nu11102536"},{"key":"24","doi-asserted-by":"publisher","unstructured":"Pafili, K. &amp; Roden, M. (2021)  Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.  <i>Mol. Metab.<\/i>, 50, 101122. https:\/\/doi.org\/10.1016\/j.molmet.2020.101122","DOI":"10.1016\/j.molmet.2020.101122"},{"key":"25","doi-asserted-by":"publisher","unstructured":"Park, M., Yoo, J.H., Lee, Y.S. &amp; Lee, H.J. (2019)  Lonicera caerulea Extract Attenuates Non-Alcoholic Fatty Liver Disease in Free Fatty Acid-Induced HepG2 Hepatocytes and in High Fat Diet-Fed Mice.  <i>Nutrients<\/i>, 11, 494. https:\/\/doi.org\/10.3390\/nu11030494","DOI":"10.3390\/nu11030494"},{"key":"26","doi-asserted-by":"publisher","unstructured":"Patel, S., Khan, H. &amp; Majumdar, A. (2022)  Crosstalk between Sirtuins and Nrf2: SIRT1 activators as emerging treatment for diabetic neuropathy.  <i>Metab. Brain Dis.<\/i>, 37, 2181-2195. https:\/\/doi.org\/10.1007\/s11011-022-00956-z","DOI":"10.1007\/s11011-022-00956-z"},{"key":"27","doi-asserted-by":"publisher","unstructured":"Purushotham, A., Schug, T.T., Xu, Q., Surapureddi, S., Guo, X. &amp; Li, X. (2009)  Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation.  <i>Cell Metab.<\/i>, 9, 327-338. https:\/\/doi.org\/10.1016\/j.cmet.2009.02.006","DOI":"10.1016\/j.cmet.2009.02.006"},{"key":"28","doi-asserted-by":"publisher","unstructured":"Qi, J., Kim, J.W., Zhou, Z., Lim, C.W. &amp; Kim, B. (2020)  Ferroptosis Affects the Progression of Nonalcoholic Steatohepatitis via the Modulation of Lipid Peroxidation-Mediated Cell Death in Mice.  <i>Am. J. Pathol.<\/i>, 190, 68-81. https:\/\/doi.org\/10.1016\/j.ajpath.2019.09.011","DOI":"10.1016\/j.ajpath.2019.09.011"},{"key":"29","doi-asserted-by":"publisher","unstructured":"Qiongyue, Z., Xin, Y., Meng, P., Sulin, M., Yanlin, W., Xinyi, L. &amp; Xuemin, S. (2022)  Post-treatment With Irisin Attenuates Acute Kidney Injury in Sepsis Mice Through Anti-Ferroptosis via the SIRT1\/Nrf2 Pathway.  <i>Front. Pharmacol.<\/i>, 13, 857067. https:\/\/doi.org\/10.3389\/fphar.2022.857067","DOI":"10.3389\/fphar.2022.857067"},{"key":"30","doi-asserted-by":"publisher","unstructured":"Recena Aydos, L., Aparecida do Amaral, L., Serafim de Souza, R., Jacobowski, A.C., Freitas Dos Santos, E. &amp; Rodrigues Macedo, M.L. (2019)  Nonalcoholic Fatty Liver Disease Induced by High-Fat Diet in C57bl\/6 Models.  <i>Nutrients<\/i>, 11, 3067. https:\/\/doi.org\/10.3390\/nu11123067","DOI":"10.3390\/nu11123067"},{"key":"31","doi-asserted-by":"publisher","unstructured":"Saiman, Y., Duarte-Rojo, A. &amp; Rinella, M.E. (2022)  Fatty Liver Disease: Diagnosis and Stratification.  <i>Annu. Rev. Med.<\/i>, 73, 529-544. https:\/\/doi.org\/10.1146\/annurev-med-042220-020407","DOI":"10.1146\/annurev-med-042220-020407"},{"key":"32","doi-asserted-by":"publisher","unstructured":"Sharma, R.S., Harrison, D.J., Kisielewski, D., Cassidy, D.M., McNeilly, A.D., Gallagher, J.R., Walsh, S.V., Honda, T., McCrimmon, R.J., Dinkova-Kostova, A.T., Ashford, M.L.J., Dillon, J.F. &amp; Hayes, J.D. (2018)  Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).  <i>Cell. Mol. Gastroenterol. Hepatol.<\/i>, 5, 367-398. https:\/\/doi.org\/10.1016\/j.jcmgh.2017.11.016","DOI":"10.1016\/j.jcmgh.2017.11.016"},{"key":"33","doi-asserted-by":"publisher","unstructured":"Sharma, R.S., Harrison, D.J., Kisielewski, D., Cassidy, D.M., McNeilly, A.D., Gallagher, J.R., Walsh, S.V., Honda, T., McCrimmon, R.J., Dinkova-Kostova, A.T., Ashford, M.L.J., Dillon, J.F. &amp; Hayes, J.D. (2018)  Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).  <i>Cell. Mol. Gastroenterol. Hepatol.<\/i>, 5, 367-398. https:\/\/doi.org\/10.1016\/j.jcmgh.2017.11.016","DOI":"10.1016\/j.jcmgh.2017.11.016"},{"key":"34","doi-asserted-by":"publisher","unstructured":"Shojaie, L., Iorga, A. &amp; Dara, L. (2020)  Cell Death in Liver Diseases: A Review.  <i>Int. J. Mol. Sci.<\/i>, 21, 9682. https:\/\/doi.org\/10.3390\/ijms21249682","DOI":"10.3390\/ijms21249682"},{"key":"35","doi-asserted-by":"publisher","unstructured":"Solano-Urrusquieta, A., Morales-Gonzalez, J.A., Castro-Narro, G.E., Cerda-Reyes, E., Flores-Rangel, P.D. &amp; Fierros-Oceguera, R. (2020)  NRF-2 and nonalcoholic fatty liver disease.  <i>Ann. Hepatol.<\/i>, 19, 458-465. https:\/\/doi.org\/10.1016\/j.aohep.2019.11.010","DOI":"10.1016\/j.aohep.2019.11.010"},{"key":"36","doi-asserted-by":"publisher","unstructured":"Sun, M., Sun, Q., Li, T., Ren, X., Xu, Q., Sun, Z. &amp; Duan, J. (2024)  Silica nanoparticles induce liver lipid metabolism disorder via ACSL4-mediated ferroptosis.  <i>Environ. Pollut.<\/i>, 359, 124590. https:\/\/doi.org\/10.1016\/j.envpol.2024.124590","DOI":"10.1016\/j.envpol.2024.124590"},{"key":"37","doi-asserted-by":"publisher","unstructured":"Teng, T., Qiu, S., Zhao, Y., Zhao, S., Sun, D., Hou, L., Li, Y., Zhou, K., Yu, X., Yang, C. &amp; Li, Y. (2022)  Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease.  <i>Int. J. Mol. Sci.<\/i>, 23, 7841. https:\/\/doi.org\/10.3390\/ijms23147841","DOI":"10.3390\/ijms23147841"},{"key":"38","doi-asserted-by":"publisher","unstructured":"Tian, C., Huang, R. &amp; Xiang, M. (2024)  SIRT1: Harnessing multiple pathways to hinder NAFLD.  <i>Pharmacol. Res.<\/i>, 203, 107155. https:\/\/doi.org\/10.1016\/j.phrs.2024.107155","DOI":"10.1016\/j.phrs.2024.107155"},{"key":"39","doi-asserted-by":"publisher","unstructured":"Tilg, H., Petta, S., Stefan, N. &amp; Targher, G. (2026)  Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review.  <i>JAMA<\/i>, 335, 163-174. https:\/\/doi.org\/10.1001\/jama.2025.19615","DOI":"10.1001\/jama.2025.19615"},{"key":"40","doi-asserted-by":"publisher","unstructured":"Tong, J., Lan, X.T., Zhang, Z., Liu, Y., Sun, D.Y., Wang, X.J., Ou-Yang, S.X., Zhuang, C.L., Shen, F.M., Wang, P. &amp; Li, D.J. (2023)  Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis.  <i>Acta Pharmacol. Sin.<\/i>, 44, 1014-1028. https:\/\/doi.org\/10.1038\/s41401-022-01010-5","DOI":"10.1038\/s41401-022-01010-5"},{"key":"41","doi-asserted-by":"publisher","unstructured":"Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D.R. &amp; Tsapas, A. (2013)  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.  <i>Ann. Intern. Med.<\/i>, 159, 262-274. https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00007","DOI":"10.7326\/0003-4819-159-4-201308200-00007"},{"key":"42","unstructured":"Wang, C., Liu, T., Tong, Y., Cui, R., Qu, K., Liu, C. &amp; Zhang, J. (2021)  Ulinastatin protects against acetaminophen-induced liver injury by alleviating ferroptosis via the SIRT1\/NRF2\/HO-1 pathway.  <i>Am. J. Transl. Res.<\/i>, 13, 6031-6042."},{"key":"43","doi-asserted-by":"publisher","unstructured":"Wang, S., Liu, Z., Geng, J., Li, L. &amp; Feng, X. (2022)  An overview of ferroptosis in non-alcoholic fatty liver disease.  <i>Biomed. <\/i><i>Pharmacother.<\/i>, 153, 113374. https:\/\/doi.org\/10.1016\/j.biopha.2022.113374","DOI":"10.1016\/j.biopha.2022.113374"},{"key":"44","doi-asserted-by":"publisher","unstructured":"Wang, Y.H., Chang, D.Y., Zhao, M.H. &amp; Chen, M. (2024)  Dapagliflozin Alleviates Diabetic Kidney Disease via Hypoxia Inducible Factor 1alpha\/Heme Oxygenase 1-Mediated Ferroptosis.  <i>Antioxid. Redox Signal.<\/i>, 40, 492-509. https:\/\/doi.org\/10.1089\/ars.2022.0169","DOI":"10.1089\/ars.2022.0169"},{"key":"45","doi-asserted-by":"publisher","unstructured":"Yang, M., Xia, L., Song, J., Hu, H., Zang, N., Yang, J., Zou, Y., Wang, L., Zheng, X., He, Q., Liu, J., Liu, F., Liang, K., Sun, L. &amp; Chen, L. (2023)  Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation.  <i>Lipids Health Dis.<\/i>, 22, 202. https:\/\/doi.org\/10.1186\/s12944-023-01969-y","DOI":"10.1186\/s12944-023-01969-y"},{"key":"46","doi-asserted-by":"publisher","unstructured":"Yang, Y., Chen, J., Gao, Q., Shan, X., Wang, J. &amp; Lv, Z. (2020)  Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease.  <i>Toxi<\/i><i>cology<\/i>, 445, 152599. https:\/\/doi.org\/10.1016\/j.tox.2020.152599","DOI":"10.1016\/j.tox.2020.152599"},{"key":"47","doi-asserted-by":"publisher","unstructured":"Ye, Q., Jiang, Y., Wu, D., Cai, J., Jiang, Z., Zhou, Z., Liu, L., Ling, Q., Wang, Q. &amp; Zhao, G. (2023)  Atractylodin alleviates nonalcoholic fatty liver disease by regulating Nrf2-mediated ferroptosis.  <i>Heliyon<\/i>, 9, e18321. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18321","DOI":"10.1016\/j.heliyon.2023.e18321"},{"key":"48","doi-asserted-by":"publisher","unstructured":"Younossi, Z., Anstee, Q.M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J. &amp; Bugianesi, E. (2018)  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.  <i>Nat. Rev. Gastroenterol. Hepatol.<\/i>, 15, 11-20. https:\/\/doi.org\/10.1038\/nrgastro.2017.109","DOI":"10.1038\/nrgastro.2017.109"},{"key":"49","doi-asserted-by":"publisher","unstructured":"Zandani, G., Anavi-Cohen, S., Yudelevich, T., Nyska, A., Dudai, N., Madar, Z. &amp; Gorelick, J. (2022)  Chiliadenus iphionoides Reduces Body Weight and Improves Parameters Related to Hepatic Lipid and Glucose Metabolism in a High-Fat-Diet-Induced Mice Model of NAFLD.  <i>Nutrients<\/i>, 14, 4552. https:\/\/doi.org\/10.3390\/nu14214552","DOI":"10.3390\/nu14214552"},{"key":"50","doi-asserted-by":"publisher","unstructured":"Zhang, J., Chen, X., Lv, S. &amp; Hao, Q. (2025a)  Dapagliflozin inhibits ferroptosis to improve chronic heart failure by regulating Nrf2\/HO-1\/GPX4 signaling pathway.  <i>PLoS One<\/i>, 20, e0317295. https:\/\/doi.org\/10.1371\/journal.pone.0317295","DOI":"10.1371\/journal.pone.0317295"},{"key":"51","doi-asserted-by":"publisher","unstructured":"Zhang, Y., Meng, T., Zuo, L., Bei, Y., Zhang, Q., Su, Z., Huang, Y., Pang, J., Xiang, Q. &amp; Yang, H. (2017)  Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models.  <i>Mar. Drugs<\/i>, 15, 163. https:\/\/doi.org\/10.3390\/md15060163","DOI":"10.3390\/md15060163"},{"key":"52","doi-asserted-by":"publisher","unstructured":"Zhang, Z., Li, L., Dai, Y., Lian, Y., Song, H., Dai, X., Su, R., Yin, J. &amp; Gu, R. (2025b)  Dapagliflozin inhibits ferroptosis and ameliorates renal fibrosis in diabetic C57BL\/6J mice.  <i>Sci. Rep.<\/i>, 15, 7117. https:\/\/doi.org\/10.1038\/s41598-025-91278-4","DOI":"10.1038\/s41598-025-91278-4"},{"key":"53","doi-asserted-by":"publisher","unstructured":"Zhao, D.M., Li, C.Q., Sun, Y.M., Fan, J.Y., Wu, N., Sun, Y.N. &amp; Sun, X.Y. (2023)  Sodium glucose cotransporter-2-inhibitor dapagliflozin improves nonalcoholic fatty liver disease by ameliorating dipeptidyl-peptidase-4 protein expression in diabetic mice.  <i>Endokrynol. Pol.<\/i>, 74, 190-196. https:\/\/doi.org\/10.5603\/EP.a2023.0018","DOI":"10.5603\/EP.a2023.0018"},{"key":"54","doi-asserted-by":"publisher","unstructured":"Zhu, Z., Zhang, Y., Huang, X., Can, L., Zhao, X., Wang, Y., Xue, J., Cheng, M. &amp; Zhu, L. (2021)  Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4.  <i>Eur. J. Pharmacol.<\/i>, 908, 174351. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174351","DOI":"10.1016\/j.ejphar.2021.174351"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/269\/4\/269_2026.J037\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:27:27Z","timestamp":1791602847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/269\/4\/269_2026.J037\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2026.j037","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2026.J037"}}